reports
Advantage Solutions Announces Date for its First Quarter 2025 Financia...
Advantage Solutions Announces Date for its First Quarter 2025 Financial Results and Conference Call ST. LOUIS, April 25, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) announced today that it will release financial results for the first quarter at 7 a.m. EDT on May 12, 2025, followed by a conference call at 8:30 a.m. EDT on the same day. The conference call can be accessed live over the phone by dialing 1-800-267-6316, or for international callers, 1-203-518-9783. The conference ID is ADVQ1. Approximately three hours after the call, a replay will be available by dialing ...
Merus gibt Annahme von Abstract zur Präsentation auf der ASCO®-Jahrest...
Merus gibt Annahme von Abstract zur Präsentation auf der ASCO®-Jahrestagung 2025 bekannt - Vorläufige klinische Daten zu Petosemtamab in Kombination mit Pembrolizumab bei 1L PD-L1+ r/m HNSCC für Posterpräsentation ausgewählt - Telefonkonferenz am Donnerstag, 22. Mai, um 17:30 Uhr Eastern Time zur Besprechung des vollständigen ASCO®-Datensatzes UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 24, 2025 (GLOBE NEWSWIRE) -- N.V. (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Onkologieunternehmen, das innovative, multispezifische Volllängen-Antikörper und Anti...
Merus annonce l’acceptation de son résumé pour présentation au congrès...
Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO® - Le pétosemtamab en association avec le pembrolizumab en traitement de première intention d'un CETC r/m PD-L1+ : premières données cliniques provisoires sélectionnées pour une présentation sous forme d’affiche - Conférence téléphonique le jeudi 22 mai à 17 h 30 heure de l’Est (« HE ») pour discuter de l’ensemble de données complet présenté lors de l’ASCO® UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 24 avr. 2025 (GLOBE NEWSWIRE) -- N.V. (Nasdaq : MRUS) (« Merus », la « Société »...
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC f...
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 1...
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® A...
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today ann...
Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Divide...
Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend SHREVEPORT, La., April 16, 2025 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (NASDAQ: HFBL), the holding company for Home Federal Bank, announced today that its Board of Directors at their meeting on April 16, 2025, declared a quarterly cash dividend of $0.13 per share on the Company’s common stock. The dividend is payable on May 12, 2025, to the shareholders of record at the close of business on April 28, 2025. Home Federal Bancorp, Inc. of Louisiana is the holding company for Home F...
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 56...
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq...
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-00...
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced completion of patie...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Fina...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. “We believe Ixo-vec is poised to ...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Na...
Merus to Participate in a Fireside Chat at the 24th Annual Needham Vir...
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET. The webcast of the pres...
Merus nimmt an Kamingespräch auf der 24. jährlichen Needham Virtual He...
Merus nimmt an Kamingespräch auf der 24. jährlichen Needham Virtual Healthcare Conference teil UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, hat heute bekanntgegeben, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, am Dienstag, 8. April 2025, um 8:45 Uhr ET (Eastern Time) an einem Kamingespräch auf der 24. jährlichen Need...
Merus participera à une discussion informelle lors de la 24e conférenc...
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 01 avr. 2025 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques et des conjugués anticorps-médicament innovants (Biclonics®, Triclonics® et ADClonics®), a annoncé aujourd’hui que le Dr Bill Lundberg, Président et PDG de Merus, participera à une discussion informelle lors de la 24e conférence annuelle virtuelle Needham sur les soins de santé, qui...
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets...
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the I...
Advantage Solutions names Dean General new Chief Operating Officer of ...
Advantage Solutions names Dean General new Chief Operating Officer of Branded Services business segment Seasoned retail executive with deep experience and connectivity in the retail and consumer goods industry to replace Jack Pestello, who announced his departure ST. LOUIS, March 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ADV), a leading provider of business solutions to consumer goods manufacturers and retailers, today announced the appointment of Dean General as the new Chief Operating Officer of its Branded Services business unit effective March 24. General will join the company’s execut...
Advantage Solutions Reports Fourth Quarter and 2024 Results: Transform...
Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company Delivered Adjusted EBITDA growth through strong execution and cost discipline Continued progress on the transformation to enhance capabilities and increase operating efficiencies Management expects growth in Revenues and Adjusted EBITDA in 2025 ST. LOUIS, March 07, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to consumer goods manufacturers ...
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo...
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMDNon-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve and previously treated patients REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWS...
Merus gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr ...
Merus gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 bekannt und berichtet über die Geschäftsentwicklung - Phase-III-Zulassungsstudien zu Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung des PD-L1-positiven rezidivierten/metastasierten Kopf-Hals-Plattenepithelkarzinoms (r/m HNSCC) und Petosemtamab als Monotherapie in der Zweit-/Drittlinienbehandlung des r/m HNSCC nehmen Patienten auf; die Rekrutierung soll bis Ende 2025 weitgehend abgeschlossen sein - Phase-II-Studie mit Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung...
Merus annonce les résultats financiers de son quatrième trimestre et d...
Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités - Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1 et l’évaluation du pétosemtamab en monothérapie de 2ᵉ et 3ᵉ ligne contre le CETC r/m ; recrutement pressenti terminé en grande partie d’ici fin 2025 - Essai de phase II portant sur le pétosemtamab en association avec le pembrolizumab en 1ᵉ ligne de traitement dans le...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
SM SM ENERGY COMPANY
SIGI SELECTIVE INSURANCE GROUP INC.
PDFS PDF SOLUTIONS INC.
OXBR OXBRIDGE RE HOLDINGS
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
HMC HARMONIC
EL ESTEE LAUDER COMPANIES INC. CLASS A
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
BZH BEAZER HOMES USA INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
AKAM AKAMAI TECHNOLOGIES INC.
OLN OLIN CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
HP HELMERICH & PAYNE INC.
HI HILLENBRAND INC.
PLBC PLUMAS BANCORP
MRUS MERUS B V
QNBC QNB CORP.
MPB MID PENN BANCORP INC.
RCUS ARCUS BIOSCIENCES
EAF GRAFTECH INTERNATIONAL
AMCR AMCOR PLC
CXDO CREXENDO
IDYA IDEAYA BIOSCIENCES
MTCH MATCH GROUP INC.
IMNM IMMUNOME
PFX PHENIXFIN CORP
VMEO VIMEO INC
FLNC FLUENCE ENERGY INC
ECBK ECB BANCORP INC.
TLSI TRISALUS LIFE SCIENCES INC
TKO TKO GROUP HOLDINGS
SSII INC.
AEI SS INNOVATIONS INTERNATIONAL INC
OCX ALSET INC.
ISPO ONCOCYTE CORPORATION
INSPIRATO INCORPORATED
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.